重组人腺病毒-p53注射液联合顺铂治疗恶性胸腹腔积液的疗效观察  

Clinical efficacy of intracavitary infusion of recombinant adenoviral human - p53 combined with cisplatin on malignant pleural effusion and ascites

作　　者：王翔[1] 张有为[1] 孙三元[1] 

机构地区：[1]徐州市中心医院肿瘤内科,江苏徐州221009

出　　处：《徐州医学院学报》2014年第11期810-813,共4页Acta Academiae Medicinae Xuzhou

基　　金：徐州市卫生局课题（XWJ2011032）.

摘　　要：目的观察重组人腺病毒-p53（rAd～p53）注射液联合顺铂（DDP）腔内化疗治疗恶性胸腹腔积液患者的疗效和安全性。方法80例恶性胸腹腔积液患者分为rAd—p53联合化疗组（治疗组，n=40）和单纯化疗组（对照组，n=40）。治疗组腔内灌注DDP 60mg和rAd—p532×10^12VP，每周2次，3周重复；对照组除不加入tAd—p53外，其余同治疗组。结果治疗组总有效率为75．0％（30／40），对照组为47．5％（19／40），治疗组总有效率明显高于对照组（P〈0．05）。2组患者均耐受良好，无严重不良反应。治疗组的中位生存期为7．4个月，略长于对照组的6．0个月，但2组间差异无统计学意义（P〉0．05）。结论腔内灌注rAd—p53联合化疗药物治疗恶性胸腹腔积液有效且安全，远期疗效尚需进一步观察。Objective To observe the efficacy and safety of intracavitary infusion of recombinant adenoviral human p53 （rAd -p53） combined with cisplatin （DDP） on malignant pleural effusion and ascites. Methods Eighty cases of patients with malignant pleural effusion and ascites were divided into two groups of intracavitary infusion of rAd - p53 combined with DDP （ treatment group, n = 40） and DDP alone （ control group, n = 40）. The treatment group received intracavitary infusion of DDP （60 mg） and rAd- p53 （2 ×10^12 VP） , twice a week, repeated once every three weeks. The same therapy was applied to the control group without adding rAd - p53. Results The total effective rate was 75. 0% （30/40） in the treatment group and 47.5% （19/40） in the control group, the difference was statistically significant （P 〈 0.05）. All the patients in both groups well tolerated the treatment and no severe side effects were observed. The median survival time was 7.4 months in the treatment group and 6.0 months in the control group, with no statistically significant difference between the two groups （P 〉 0.05 ）. Conclusion Intracavitary infusion of tad - p53 combined with chemotherapeutic agents is effective and secure for the treatment of malignant pleural effusion and ascites, but long - term efficacy requires further observation.

关 键 词：恶性胸腹腔积液 重组人腺病毒-p53 腔内化疗 

分 类 号：R730.5[医药卫生—肿瘤]